Table 5.
Treatment allocation for patients in the subgroup of patients with low-risk prostate cancer (Gleason ≤6, Stage 1, and PSA <10 ng/mL) and available data on biopsy tumour volume (n = 291), stratified by volume of prostate cancer
| RadOnc (n, %) | Urologist alone (n, %) | |
|---|---|---|
| Low-volume prostate cancer (≤2 positive cores) | ||
| No treatment | 38 (62.3) | 118 (88.1) |
| Any treatment | 23 (37.7) | 16 (11.9) |
| Radiation | 16 (26.2) | <5 |
| EBRT | 10 (16.4) | 0 |
| Brachytherapya | 6 (9.8) | <5 |
| Surgery | 7 (11.5) | 11-15 |
| High-volume prostate cancer (≥3 positive cores) | ||
| No treatment | 17 (34.0) | 33 (71.7) |
| Any treatment | 33 (66.0) | 13 (28.3) |
| Radiation | 26 (52.0) | 7 (15.3) |
| EBRT | 13 (26.0) | <5 |
| Brachytherapya | 13 (26.0) | <5 |
| Surgery | 7 (14.0) | 6 (13.0) |
Note: in order to comply with ICES privacy regulations, cell sizes smaller than 5 were suppressed. Where cells <5 would be calculable, the next smallest cell in the category was also suppressed
EBRT external beam radiotherapy
a Includes both low-dose rate (LDR) and high-dose rate (HDR) brachytherapy